Novamind is building the infrastructure required for a regulated psychedelics industry
— Stanislav Grof, MD
We are developing the infrastructure required for a regulated psychedelics industry.
Ketamine-assisted psychotherapy & other innovative therapies
Legal, medically supervised psychedelic experiences
Clinical research for psychedelic medicines
Novamind is growing a network of specialized psychedelic clinics and retreats
Treatment is provided by blending evidence-based principles with psychedelic medicines
We guide individuals through their entire healing journey, both at home and abroad
Novamind enables safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites.
We provide ketamine-assisted psychotherapy and other novel treatments through our network of Cedar Psychiatry clinics and operate Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine.
Through our retreat partners, we offer additional access to psychedelics in jurisdictions with established regulations for the use of these alternative medicines.
March 03, 2021
Novamind Expands Leadership Team, Accelerating M&A
March 01, 2021
Novamind Reports Company Highlights and Strong Revenue Growth in Fiscal Second Quarter
February 23, 2021
Novamind to Present at Benzinga Conference
February 22, 2021
Novamind Fast Tracked for Inclusion in Horizons Psychedelic ETF